Recombinant Anti-Bcl10 antibody [ep605y] (ab40752)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [ep605y] to Bcl10
- Suitable for: Flow Cyt (Intra), WB, IHC-P, IP
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Bcl10 antibody [ep605y]
See all Bcl10 primary antibodies -
Description
Rabbit monoclonal [ep605y] to Bcl10 -
Host species
Rabbit -
Specificity
Not suitable for mouse IHC-P.
-
Tested applications
Suitable for: Flow Cyt (Intra), WB, IHC-P, IPmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide within Human Bcl10 (N terminal). The exact sequence is proprietary.
-
Positive control
- WB: Raji, WEHI-231, RAW 264.7 whole cell and mouse spleen tissue lysates. Flow Cyt (intra): Daudi cells. IP: Daudi and WEHI-231 whole cell lystates. IHC-P: Human colon carcinoma.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
ep605y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab40752 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt (Intra) |
1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB |
1/2000. Detects a band of approximately 32 kDa (predicted molecular weight: 31 kDa).
|
|
IHC-P |
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
|
IP |
1/30 - 1/50.
|
Notes |
---|
Flow Cyt (Intra)
1/100. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
WB
1/2000. Detects a band of approximately 32 kDa (predicted molecular weight: 31 kDa). |
IHC-P
Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
IP
1/30 - 1/50. |
Target
-
Function
Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK. May be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex. Is a substrate for MALT1. -
Tissue specificity
Ubiquitous. -
Involvement in disease
Note=A chromosomal aberration involving BCL10 is recurrent in low-grade mucosa-associated lymphoid tissue (MALT lymphoma). Translocation t(1;14)(p22;q32). Although the BCL10/IgH translocation leaves the coding region of BCL10 intact, frequent BCL10 mutations could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
Note=Defects in BCL10 are involved in various types of cancer. -
Sequence similarities
Contains 1 CARD domain. -
Post-translational
modificationsPhosphorylated. Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2. -
Cellular localization
Cytoplasm > perinuclear region. Membrane raft. Appears to have a perinuclear, compact and filamentous pattern of expression. Also found in the nucleus of several types of tumor cells. Colocalized with DPP4 in membrane rafts. - Information by UniProt
-
Database links
- Entrez Gene: 8915 Human
- Entrez Gene: 12042 Mouse
- Omim: 603517 Human
- SwissProt: O95999 Human
- SwissProt: Q9Z0H7 Mouse
- Unigene: 193516 Human
- Unigene: 239141 Mouse
-
Alternative names
- AI132454 antibody
- B cell CLL/lymphoma 10 antibody
- B cell lymphoma/leukemia10 antibody
see all
Images
-
32 kDa Bcl10 was immunoprecipitated from 0.35mg WEHI-231 (mouse B cell lymphoma B lymphocyte ), whole cell lysate with ab40752 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab40752 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/1000 dilution.
Lane 1 (Input): WEHI-231 (mouse B cell lymphoma B lymphocyte ), whole cell lysate 10 μg.
Lane 2 (+): WEHI-231 whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab40752 in WEHI-231 whole cell lysate.
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Exposure time: 102 seconds.
-
32 kDa Bcl10 was immunoprecipitated from 0.35mg of Daudi (human Burkitt's lymphoma lymphoblast) whole cell lysate with ab40752 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab40752 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/1000 dilution.
Lane 1 (Input): Daudi (human Burkitt's lymphoma lymphoblast) whole cell lysate 10 μg.
Lane 2 (+): Daudi whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab40752 in Daudi whole cell lysate.
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Exposure time: 32 seconds.
-
All lanes : Anti-Bcl10 antibody [ep605y] (ab40752) at 1/2000 dilution
Lane 1 : WEHI-231 (mouse B cell lymphoma B lymphocyte) whole cell lysate
Lane 2 : RAW 264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysate
Lane 3 : Mouse spleen tissue lysate
Lane 4 : Mouse kidney tissue lysate
Lane 5 : Mouse bone marrow lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 31 kDa
Exposure time: 103 secondsBlocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
ab129002 was used as a loading control.
The expression profile observed is consistent with what has been described in the literature (PMID: 10319863).
-
Anti-Bcl10 antibody [ep605y] (ab40752) at 1/2000 dilution + Raji cell lysate at 10 µg
Predicted band size: 31 kDa
Observed band size: 32 kDa why is the actual band size different from the predicted? -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Bcl10 antibody [ep605y] (ab40752)
Immunohistochemical analysis of paraffin-embedded human colon carcinoma using ab40752 at a dilution of 1/50.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
-
Intracellular Flow Cytometry analysis of Daudi (Human Burkitt's lymphoma lymphoblast) cells labeling Bcl10 with purified ab40752 at 1/100 dilution (10 µg/mL) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cells without incubation with primary antibody and secondary antibody (Blue).
-
Purified ab40752 at 1/50 dilution (2µg) immunoprecipitating Bcl10 in Daudi whole cell lysate.
Lane 1 (input): Daudi (Human Burkitt's lymphoma B lymphocyte) whole cell lysate 10µg
Lane 2 (+): ab40752 + Daudi whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab40752 in Daudi whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Observed band size: 32 kDa
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab40752 has been referenced in 1 publication.
- Ginster S et al. Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation. PLoS One 12:e0169026 (2017). WB . PubMed: 28052131